GHK-Cu Monitoring Schedule: Labs & Exams You Need

Is there a GHK-Cu monitoring schedule?

No. A lab schedule needs a defined product and a defined dose, and GHK-Cu has neither. It is the copper(II) complex of GHK, a tripeptide found in human plasma, saliva and urine whose levels decline with age [8]. No FDA-approved drug is known to contain it [1][9]. Compounded drugs are not FDA-reviewed for safety, effectiveness or quality before they are marketed [10]. Topical copper peptide serums and creams sold as cosmetics need no FDA approval before sale, and a product marketed to treat disease or affect the body's structure or function would be a drug [5]. HealthRX.com offers a copper peptide cream.

What the human studies measured

A 2006 randomized trial tested GHK-Cu skin care after circumoral CO2 laser resurfacing, with 13 patients completing it. Computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality, while the patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [3].

A 1992 prospective randomized evaluator-blinded trial of 86 patients with venous stasis ulcers found a 0.4% tripeptide copper complex cream no different from an inert vehicle placebo for ulcer size, while silver sulfadiazine 1% did reduce ulcer size [4].

A 2026 systematic review of 64 retained records describes the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [11].

What FDA says about injectable GHK-Cu

Injectable GHK-Cu appears on FDA's list of bulk substances nominated for compounding but withdrawn. FDA's stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [2].

Non-injectable GHK-Cu sits in category 1, the group FDA is still evaluating for the compounding list. FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027; no vote has taken place [1][12].

Where copper lab values do come from

The nearest copper reference is the label for copper (cupric chloride) injection, an intravenous supplement for total parenteral nutrition, a different drug, route and patient group [6]. The label gives normal serum copper values of 80 to 163 mcg/dL (mean about 110 mcg/dL). For patients with cholestasis, biliary dysfunction or cirrhosis, it says to monitor hepatic and biliary function during long-term administration, and to obtain serum copper and ceruloplasmin if hepatobiliary signs develop; it warns that copper given in Wilson disease may increase hepatic copper accumulation and aggravate hepatocellular degeneration. It also says acute copper toxicity has been reported with oral, intravenous and subcutaneous administration and has included nausea, vomiting, abdominal pain, encephalopathy and multi-organ failure that may be fatal [6]. That label does not cover GHK-Cu.

Zinc and copper

Long-term, high-dose zinc supplementation can interfere with copper uptake, and many of zinc's toxic effects are due to copper deficiency [7].